TIMP-1: a Strong Player in Colorectal Cancer
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In t h is issu e of t he J Gastrointestin Liver Dis, Ionescu et al evaluate, in a pilot study, the potential prognostic impact of a panel of six genes (CDH1, SMAD3, TGFβ1, ICAM-1, TIMP-1 and MUC12) in colorectal cancer (CRC) patients [1] . ese genes have been studied by RT- useful for clinicians to have additional preoperative prognostic indicators available, in order to better identify patients who really require adjuvant or neoadjuvant treatment. us, there is a need for additional tumor-associated antigens at the time of clinical presentation, eligible as prognostic markers in CRC [2] [3] [4] .
Proteolytic enzymes are important in the breakdown and reconstitution of basement membrane and extracellular matrix components (ECM) in tissue remodelling, wound repair, inflammatory responses, angiogenesis, destructive diseases, as well as CRC invasion and metastasis [5, 6] . Matrix metalloproteinases (MMPs) consist of a family of zincdependent endopeptidases implicated in the degradation and remodelling of ECM components. eir activity is crucial in CRC growth and the multistep processes of invasion, metastasis and angiogenesis. MMPs are controlled by endogenous tissue speci c inhibitors, called tissue inhibitors of metalloproteinases (TIMPs). e imbalance between MMPs and TIMPs is an essential step in the development of CRC and is of critical impact in early events of tumor progression. TIMPs might display a dual in uence on CRC progression and metastasis: on the one hand they directly regulate and inhibit MMPs and on the other hand they inhibit the apoptosis of tumor cells, in uence angiogenesis and nally, facilitate tumor growth and metastasis [7] [8] [9] . Four TIMPs have been characterized in humans (TIMP-1, -2, -3 and TIMP-4). TIMP-1 inhibits angiogenesis either directly or indirectly via restraining MMP-9-mediated release of vascular endothelial growth factor (VEGF) from matrix [10] .
Several studies have demonstrated an increased expression of MMPs and TIMPs in CRC. It has also been shown that high preoperative serum or plasma MMPs and TIMP-1 antigen levels are strongly predictive factors for a poor prognosis in patients with CRC and their assessment might be useful for the identi cation of patients with a higher risk for cancer recurrence. We and others have also proposed that MMPs and TIMP-1 might play a part not only in CRC invasion and initiation of metastasis but also in colorectal carcinogenesis from colorectal adenomas [11] [12] [13] [14] [15] .
Strong evidence supports the concept of the use of MMPs as targets for cancer therapy. Several therapeutic MMP inhibitors (MMPIs) have been developed to target MMPs and were tested in phase III clinical trials in humans. In contrast to their promising e ect in preclinical models, most of these agents unfortunately failed in clinical trials. e use of broadspectrum MMPIs may lead to undesired adverse events because of the wide range of MMPs that are inhibited [16, 17] . e development of a new generation of selective inhibitors highly speci c for certain MMPs with improved pharmacokinetic properties is a major challenge for the near future. eir use in combination with classical chemotherapeutic strategies might have the potential to become supplementary oncological treatment modalities [18] [19] [20] [21] [22] .
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